TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

GENOTROPIN

SOMATROPIN
Metabolic Approved 1995-08-24

GENOTROPIN is a recombinant human growth hormone indicated for the treatment of growth failure in pediatric patients and growth hormone deficiency in adults. In children, it is used to treat growth failure associated with growth hormone deficiency, Prader-Willi syndrome, Turner syndrome, idiopathic short stature, and being born small for gestational age without catch-up growth. For adults, the medication serves as a replacement therapy for endogenous growth hormone deficiency resulting from either childhood-onset or adult-onset causes. The drug provides a therapeutic means to address both physical growth limitations and metabolic deficiencies related to inadequate hormone secretion.

Source: FDA Label • PHARMACIA

How GENOTROPIN Works

GENOTROPIN is a recombinant human growth hormone that is therapeutically equivalent to the hormone naturally produced by the pituitary gland. In pediatric patients, the medication stimulates linear growth and normalizes concentrations of Insulin-like Growth Factor-I (IGF-I). In adults with growth hormone deficiency, the drug works to reduce fat mass, increase lean body mass, and induce beneficial changes in lipid metabolism. By replacing deficient levels of endogenous hormone, it restores biological processes necessary for growth and metabolic regulation.

Source: FDA Label
6
Indications
--
Phase 3 Trials
2
Priority Reviews
30
Years on Market

Details

Status
Prescription
First Approved
1995-08-24
Routes
INJECTION
Dosage Forms
INJECTABLE

Companies

Active Ingredient: SOMATROPIN

GENOTROPIN Approval History

Loading approval history...

What GENOTROPIN Treats

5 indications

GENOTROPIN is approved for 5 conditions since its original approval in 1995. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Growth Hormone Deficiency
  • Prader-Willi Syndrome
  • Small for Gestational Age
  • Turner Syndrome
  • Idiopathic Short Stature
Source: FDA Label
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

GENOTROPIN FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

GENOTROPIN is a recombinant human growth hormone indicated for: • Pediatric: Treatment of children with growth failure due to growth hormone deficiency (GHD), Prader-Willi syndrome, Small for Gestational Age, Turner syndrome, and Idiopathic Short Stature • Adult: Treatment of adults with either adult onset or childhood onset GHD 1.1 Pediatric Patients GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous growth hormone. GENOTROPIN is indicated for the treatment of pediatric patients who have growth failure due to Pr...

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.